[go: up one dir, main page]

BR0214962A - Composição para tratar distúrbios neurocerebrovasculares - Google Patents

Composição para tratar distúrbios neurocerebrovasculares

Info

Publication number
BR0214962A
BR0214962A BR0214962-1A BR0214962A BR0214962A BR 0214962 A BR0214962 A BR 0214962A BR 0214962 A BR0214962 A BR 0214962A BR 0214962 A BR0214962 A BR 0214962A
Authority
BR
Brazil
Prior art keywords
composition
fraction
neurocerebrovascular disorders
disorders
lipid
Prior art date
Application number
BR0214962-1A
Other languages
English (en)
Inventor
Madhur Ray
Raghwendra Pal
Satyawan Singhi
Nandoo Mal Khanna
Original Assignee
Council Scient Ind Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Council Scient Ind Res filed Critical Council Scient Ind Res
Publication of BR0214962A publication Critical patent/BR0214962A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/121—Ketones acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Cardiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)

Abstract

"COMPOSIçãO PARA TRATAR DISTúRBIOS NEUROCEREBROVASCULARES". A presente invenção se refere a uma composição A obtida a partir do extrato lipídio-solúvel de rizomas e folhas de espécie Curcuma da família Zingiberaceae, útil para o tratamento de distúrbios neurocerebrovasculares, a referida composição compreendendo a fração A que consiste de arturmerona de fórmula (1), e turmerona de fórmula (2), e/ou juntamente com a fração B que consiste de curcumeno e zingiberina, e/ou a fração C que consiste de germacrona, curcumerona, zedoarona, sedoarondiol, isozdedoaronidiol, curcumenona, e curlona, e/ou aditivos farmaceuticamente aceitáveis e um método de tratamento de distúrbios neurocerebrovasculares em animais incluindo humanos usando a referida composição mediante administrar quantidade terapeuticamente efetiva do extrato lipídio-solúvel.
BR0214962-1A 2001-12-14 2002-12-14 Composição para tratar distúrbios neurocerebrovasculares BR0214962A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34016501P 2001-12-14 2001-12-14
PCT/IB2002/005366 WO2003051380A2 (en) 2001-12-14 2002-12-14 Compositions containeing curcuma extracts for the treatment of neurocerebrovascular disorders

Publications (1)

Publication Number Publication Date
BR0214962A true BR0214962A (pt) 2004-12-14

Family

ID=23332163

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0214962-1A BR0214962A (pt) 2001-12-14 2002-12-14 Composição para tratar distúrbios neurocerebrovasculares

Country Status (19)

Country Link
US (2) US20060051438A1 (pt)
EP (1) EP1453528B1 (pt)
JP (1) JP4695839B2 (pt)
KR (1) KR101001815B1 (pt)
CN (1) CN100528149C (pt)
AU (2) AU2002348802A1 (pt)
BR (1) BR0214962A (pt)
CA (1) CA2473874C (pt)
DE (1) DE60233069D1 (pt)
EA (1) EA007067B1 (pt)
EE (1) EE05374B1 (pt)
GE (1) GEP20084442B (pt)
LT (1) LT5284B (pt)
LV (1) LV13250B (pt)
MX (1) MXPA04005680A (pt)
NO (1) NO332066B1 (pt)
UA (1) UA82057C2 (pt)
WO (1) WO2003051380A2 (pt)
ZA (1) ZA200404648B (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080312333A1 (en) * 2004-05-31 2008-12-18 Kaneka Corporation Agent for Preventing/Ameliorating Life Style-Related Diseases Containing Turmeric Essential Oil Component
WO2006118079A1 (ja) * 2005-04-28 2006-11-09 Arata Yamasaki 皮膚の老化防止剤
US9492402B2 (en) 2005-05-30 2016-11-15 Benny Antony Formulation of curcuminoids with enhanced bioavailability of curcumin, demethoxycurcumin, bisdemethoxycurcumin and method of preparation and uses thereof
US8859020B2 (en) 2005-05-30 2014-10-14 Benny Antony Treatment of alzheimer's with a curcuminoid mixture and essential oil of turmeric having 45% Ar-turmerone
US12053438B2 (en) 2005-05-30 2024-08-06 Arjuna Natural Private Limited Formulation of curcuminoids with enhanced bioavailability of curcumin, demethoxycurcumin, bisdemethoxycurcumin and method of preparation and uses thereof
US10543277B2 (en) 2005-05-30 2020-01-28 Arjuna Natural Private Limited Formulation of curcumin with enhanced bioavailability of curcumin and method of preparation and treatment thereof
US10286027B2 (en) 2005-05-30 2019-05-14 Arjuna Natural Extracts, Ltd. Sustained release formulations of curcuminoids and method of preparation thereof
WO2006129323A1 (en) 2005-05-30 2006-12-07 Antony Benny A composition to enhance the bioavailability of curcumin
US7883728B2 (en) 2005-05-30 2011-02-08 Arjuna Natural Extracts, Ltd. Composition to enhance the bioavailability of curcumin
JP4980626B2 (ja) * 2006-02-28 2012-07-18 ポーラ化成工業株式会社 プラスミノーゲンアクチベーターインヒビターｉ阻害剤及びそれを配合してなる食品組成物
JP5207341B2 (ja) * 2006-10-26 2013-06-12 独立行政法人産業技術総合研究所 炎症性サイトカイン産生抑制剤
MX2010003726A (es) 2007-10-03 2010-09-14 Sabell Corp Composiciones herbarias y metodos de tratamiento de trastornos hepaticos.
JP2012519197A (ja) * 2009-03-05 2012-08-23 キージーン・エン・フェー Ｒ−クルクメンをベースとする植物揮発性物質
AU2010278711A1 (en) 2009-07-31 2012-02-23 Cognition Therapeutics, Inc. Inhibitors of cognitive decline
JP5764288B2 (ja) * 2009-09-24 2015-08-19 ハウス食品グループ本社株式会社 ウコン抽出物とガジュツ抽出物とを含有する組成物
JP5578822B2 (ja) * 2009-09-25 2014-08-27 株式会社ピカソ美化学研究所 アセチルコリンエステラーゼ阻害剤
BR112013019775A2 (pt) 2011-02-02 2017-04-18 Cognition Therapeutics Inc composto, composição farmacêutica e método para tratar declínio cognitivo ou doença de alzheimer em um paciente
US9068141B2 (en) 2011-03-29 2015-06-30 Council Of Scientific & Industrial Research Process for the modification of Curcuma aromatica essential oil
GB201111319D0 (en) 2011-07-04 2011-08-17 Univ Leuven Kath Anticonvulsant activity of tumeric oil and bisabolene sesquiterpenoids of curcuma longa
KR101832284B1 (ko) * 2012-01-13 2018-02-26 주식회사 엘지생활건강 피부 주름 개선 및 탄력 증진용 조성물
CN102697757B (zh) * 2012-05-18 2014-06-04 广州军区广州总医院 对羟基苄叉丙酮在制备预防和/或治疗脑病药物中的应用
JP2014201528A (ja) * 2013-04-02 2014-10-27 クラシエ製薬株式会社 抗酸化剤
DK3099296T3 (en) 2014-01-31 2019-04-15 Cognition Therapeutics Inc ISO-INDOLINE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE
CN104840451B (zh) * 2014-09-23 2017-04-05 桂林八加一药业股份有限公司 一种用于治疗冠心病、高脂血症的中药有效部位、制备方法及从中分离有效成分的方法
CN105738546B (zh) * 2014-12-12 2020-01-21 桂林八加一药业股份有限公司 毛郁金药材指纹图谱的建立方法及其指纹图谱
CN105055449B (zh) * 2015-07-27 2019-08-09 中国科学院西北高原生物研究所 一种具有抗炎镇痛活性的塞隆骨提取物、制备方法及中药制剂
CN106491997A (zh) * 2016-12-29 2017-03-15 王明金 一种抗精神障碍的中药组合物及其制备方法
CN106491996A (zh) * 2016-12-29 2017-03-15 王明金 一种治疗狂躁症的中药组合物及其制备方法
CN106511784A (zh) * 2016-12-29 2017-03-22 王明金 一种治疗精神疾病的中药组合物及其制备方法
CN106492137A (zh) * 2016-12-29 2017-03-15 王明金 一种治疗抑郁症的中药组合物及其制备方法
CA3063338A1 (en) * 2017-05-12 2019-12-05 House Wellness Foods Corporation Anti-inflammatory composition
EP3634394A4 (en) 2017-05-15 2021-04-07 Cognition Therapeutics, Inc. COMPOSITIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
US10391138B2 (en) * 2017-07-11 2019-08-27 Muniyal Ayurvedic Research Centre Multidimensional approach for Cancer treatment
CN108498755B (zh) * 2018-04-17 2021-04-09 贾洪章 治疗心脑血管疾病的中药组合物及其制备方法和用途
US20210267914A1 (en) * 2018-06-29 2021-09-02 House Wellness Foods Corporation A Composition for Treatment, Prevention, or Amelioration of Alzheimer's Disease, a Composition for Suppression of Brain Nerve Cell Death, a Composition for Suppression of Microglia Activation Induced by Amyloid Beta Peptide, and a Composition for Suppression of PGE2, TNF-alpha, or IL-1beta Production Induced by Amyloid Beta Peptide
CN111617059B (zh) * 2020-05-29 2023-07-25 广东工业大学 莪术二酮的应用
CN111617060A (zh) * 2020-05-29 2020-09-04 广东工业大学 吉马酮的应用
JP7637357B2 (ja) 2020-09-29 2025-02-28 学校法人近畿大学 血管保護のためのターメリックオイルを含有する組成物、ならびにこのような組成物を含む飲食品および香料

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU83350A1 (fr) 1981-05-08 1983-03-24 Oreal Composition destinee au traitement des fibres keratiniques a base de polymere cationique et de polymere anionique a groupements vinylsulfoniques et procede de traitement la mettant en oeuvre
IN162441B (pt) 1984-12-26 1988-05-28 Council Scient Ind Res
US4842859A (en) * 1986-09-08 1989-06-27 Yaguang Liu Pharmaceutical compositions for reducing hyperlipidemia and platelet-aggregation
US5120538A (en) * 1990-02-05 1992-06-09 Pt Darya-Varia Laboratoria Combinations of compounds isolated from curcuma spp as anti-inflammatory agents
US5863938A (en) * 1991-03-01 1999-01-26 Warner Lambert Company Antibacterial-wound healing compositions and methods for preparing and using same
CN1100321A (zh) * 1994-03-27 1995-03-22 叶启智 灵猫香或其复方药用针剂
WO2001030335A2 (en) * 1999-10-22 2001-05-03 The Board Of Trustees Of The University Of Illinois Pharmaceutical compositions useful in the prevention and treatment of beta-amyloid protein-induced disease
DE10029770A1 (de) * 2000-06-16 2001-12-20 Transmit Technologietransfer Verwendung von Curcuminen zur Behandlung von soliden Tumoren,insbesondere von Hirntumoren
JP2002030081A (ja) * 2000-07-13 2002-01-29 Shiseido Co Ltd ジアリールヘプタノイド誘導体及びマトリックスメタロプロテアーゼ活性阻害剤
KR20020073847A (ko) * 2001-03-16 2002-09-28 주식회사 바이오시너젠 쿠르쿠민 또는 울금 추출물을 포함하는 치매 예방 및치료용 조성물

Also Published As

Publication number Publication date
NO20043000L (no) 2004-07-13
WO2003051380A2 (en) 2003-06-26
LT5284B (lt) 2005-11-25
CN1615144A (zh) 2005-05-11
KR101001815B1 (ko) 2010-12-15
EA007067B1 (ru) 2006-06-30
KR20040073478A (ko) 2004-08-19
JP4695839B2 (ja) 2011-06-08
AU2009212969B2 (en) 2011-06-02
WO2003051380A3 (en) 2004-06-17
US20100093870A1 (en) 2010-04-15
LT2004060A (en) 2005-06-27
LV13250B (en) 2006-02-20
EP1453528A2 (en) 2004-09-08
CN100528149C (zh) 2009-08-19
DE60233069D1 (de) 2009-09-03
AU2009212969A1 (en) 2009-10-01
MXPA04005680A (es) 2004-10-15
EE200400097A (et) 2004-10-15
EP1453528B1 (en) 2009-07-22
CA2473874C (en) 2011-11-22
ZA200404648B (en) 2005-11-30
NO332066B1 (no) 2012-06-18
CA2473874A1 (en) 2003-06-26
US20060051438A1 (en) 2006-03-09
AU2002348802A1 (en) 2003-06-30
JP2005516930A (ja) 2005-06-09
EA200400807A1 (ru) 2004-12-30
EE05374B1 (et) 2011-02-15
GEP20084442B (en) 2008-08-10
UA82057C2 (en) 2008-03-11

Similar Documents

Publication Publication Date Title
BR0214962A (pt) Composição para tratar distúrbios neurocerebrovasculares
BR0116370A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar em um paciente.
BR0310099A (pt) método para tratar dislipidemia ou uma doença associada com a dislipidemia
BR0211119A (pt) Composto, método de tratar um paciente que tenha, ou de prevenir um paciente de pegar, uma doença ou condição, uso de um composto, e, método para fabricar um composto
BRPI0412526A (pt) composto, uso de um composto, composição farmacêutica, formulação em aerossol farmacêutica, e, método para o tratamento de um paciente humano ou animal com uma condição anti-inflamatória e/ou alérgica
BR0314308A (pt) Composto, composição farmacêutica, métodos para bloquear uma combinação de mu, kappa, delta ou receptor (heterodìmero) dos mesmos em mamìferos, para tratar ou prevenir obesidade e doenças relacionadas, para suprimir o apetite em um paciente em necessidade deste, e para realizar a perda de peso em um paciente obeso, e, uso de um composto
BR0013122A (pt) Ciclobenzaprina para tratamento de distúrbio de ansiedade generalizado e composições de ciclobenzaprina
BR0213540A (pt) Compostos, método para o tratamento de enfermidades ou distúrbios em um paciente e composição farmacêutica que compreende os mesmos
BR0317747A (pt) Método de tratamento terapêutico concomitante de um indivìduo, composição farmacêutica, kit, uso de um primeiro agente e um segundo agente, e, métodos de prevenir ou tratar uma doença relacionada com amilóide-b, doença de alzheimer e insuficiência cognitiva suave
ATE291433T1 (de) Extrakte von mutterkraut (tanacetum parthenium) gegen entzündliche erkrankungen
BR0115427A (pt) Composto, composição farmacêutica, métodos para inibir a liberação de peptìdeo beta-amilóide e/ou sua sìntese, para tratar a doença de alzheimer, e para prevenir a doença e o progresso da doença de alzheimer, e, uso de um composto
ATE450269T1 (de) Peptid pyyä3-36ü zur behandlung von stoffwechselkrankheiten
BRPI0414428A (pt) composições farmacêuticas
UY26130A1 (es) Compuestos para tratar la obesidad
MY146351A (en) Compositions for treating infection in cattle and swine
BRPI0406883A (pt) Composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto
BR0314511A (pt) Seleção e uso de bactérias de ácido lático para reduzir a inflamação causada por helicobater
PT1562954E (pt) Antagonistas de ccr1 para o tratamento da doenca desmielinzante inflamatoria i.a.
BR0208052A (pt) Composição que inibe matriz metaloproteinases para o tratamento de doenças neoplásicas
BRPI0409796A (pt) uso de dipiridamol ou mopidamol para tratamento e prevenção de doenças tromboembolìticas e distúrbios provocados pela formação excessiva de trombina e/ou pela expressão elevada de receptores de trombina
BR0316523A (pt) Composto, composição farmacêutica e método para tratar ou prevenir câncer em um paciente
BR0312696A (pt) Tratamento tópico de doenças da pele
BR0313413A (pt) Uso da vacinação beta amilóide juntamente com um inibidor da cox-2 seletivo para o tratamento da doença de alzheimer
BR0310061A (pt) Métodos para o tratamento de doenças e condições respiratórias com um inibidor seletivo da inos e um inibidor da pde e suas composições
BR0201524A (pt) Tratamento de combinação para ansiedade e depressão

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08L Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 10A E 11A ANUIDADES.

B07F Notification of approval that there is no relation to art. 229 of lpi (pipeline patents) [chapter 7.6 patent gazette]

Free format text: NOTIFICACAO DE NAO ANUENCIA RELACIONADA COM O ART. 229 DA LPI

B15K Others concerning applications: alteration of classification

Ipc: A61K 31/121 (2006.01), A61K 31/12 (2006.01), A61K

B08I Publication cancelled [chapter 8.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2258 DE 15/04/2014 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 10A, 11A, 12A, 13A, 14A, 15A, 16A E 17A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.